IMMUNOTHERAPY Benefit with anti-PD-L1

被引：2
|
作者：
Romero, Diana
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 02期
关键词：
D O I：
10.1038/nrclinonc.2016.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1 /PD-1 immunotherapy
    Ioannou, Nikolaos
    Hagner, Patrick R.
    Stokes, Matt
    Gandhi, Anita K.
    Apollonio, Benedetta
    Fanous, Mariam
    Papazoglou, Despoina
    Sutton, Lesley-Ann
    Rosenquist, Richard
    Amini, Rose-Marie
    Chiu, Hsiling
    Lopez-Girona, Antonia
    Janardhanan, Preethi
    Awan, Farrukh T.
    Jones, Jeffrey
    Kay, Neil E.
    Shanafelt, Tait D.
    Tallman, Martin S.
    Stamatopoulos, Kostas
    Patten, Piers E. M.
    Vardi, Anna
    Ramsay, Alan G.
    BLOOD, 2021, 137 (02) : 216 - 231
  • [32] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [33] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [34] Phthalocyanine-based photosensitizers combined with anti-PD-L1 for highly efficient photodynamic immunotherapy
    Zheng, Bi-Yuan
    Li, Song-Zi
    Zheng, Bing-De
    Ying, Jia-Wen
    Hu, Qing-Yan
    Peng, Xiao-Hui
    Li, Xingshu
    Ke, Mei-Rong
    Huang, Jian-Dong
    DYES AND PIGMENTS, 2021, 185
  • [35] FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
    Lu, Lu
    Jiang, Yi-Xin
    Liu, Xiao-Xia
    Jin, Jin-Mei
    Gu, Wen-Jie
    Luan, Xin
    Guan, Ying-Yun
    Zhang, Li-Jun
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [36] Cordycepin mediates pyroptosis in HCC through the upregulation of TXNIP and synergizes with anti-PD-L1 immunotherapy
    Liang, Bu-Gang
    Zheng, Yi-Min
    Shen, Hong-Ye
    Yang, Guo-Huan
    Xu, Wen-Xin
    Tan, Chang-Jun
    Ke, Ai-Wu
    Qin, Wen-Zheng
    HEPATOLOGY COMMUNICATIONS, 2025, 9 (03)
  • [37] Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy
    Xu, Mengxin
    Han, Yuxiang
    Liu, Guizhong
    Xu, Yang
    Duan, Dongban
    Liu, Hui
    Du, Felix
    Luo, Peter
    Liu, Zhibo
    MOLECULAR PHARMACEUTICS, 2018, 15 (10) : 4426 - 4433
  • [38] Oral delivery of anti-PD-L1 antibody for cancer immunotherapy against orthotopic colorectal tumors
    Chen, Linfu
    Zhang, Lin
    Zhao, Rui
    Shen, Jingjing
    Wang, Yingyao
    Zhu, Jiafei
    Fang, Huapan
    Liu, Nanhui
    Wang, Cheng
    Wei, Ting
    Chai, Yu
    Li, Maoyi
    Wu, Chenghao
    Chen, Qian
    Liu, Zhuang
    NANO TODAY, 2023, 50
  • [39] Nanoparticle-Mediated Explosive Anti-PD-L1 Factory Built in Tumor for Advanced Immunotherapy
    Park, Mihyeon
    Lim, Junha
    Lee, Seohee
    Nah, Yunyoung
    Kang, Yeoul
    Kim, Won Jong
    ADVANCED MATERIALS, 2025,
  • [40] Combination of lipopolysaccharide and polygalacturonic acid exerts antitumor activity and augments anti-PD-L1 immunotherapy
    Song, Jie
    Li, Jiaxin
    Zhang, Anping
    Tan, Xiaobin
    Li, Sujuan
    Luo, Lixia
    Wang, Sen
    Wei, Guoli
    Zhang, Zhenhai
    Huo, Jiege
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 281
12345